SEARCH

SEARCH BY CITATION

References

  • Arora R. C. and Meltzer H. Y. (1990) 3H-imipramine binding in the blood platelets of normal twins. Psychiatry Res. 32, 265273.
  • Azzadin A., Mysliwiec J., Wollny T., Mysliwiec M. and Buczko W. (1995) Serotonin is involved in the pathogenesis of hypertension developing during erythropoietin treatment in uremic rats. Thromb. Res. 77, 217224.
  • Bengel D., Murphy D. L., Andrews A. M., Wichems C. H., Feltner D., Heils A., Mossner R., Westphal H. and Lesch, K. (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice. Mol. Pharmacol. 53, 649655.
  • Bernstein E. M. and Quick M. W. (1999) Regulation of gamma-aminobutyric acid (GABA) transporters by exogenous GABA. J. Biol. Chem. 274, 889895.
  • Blakely R. D., Berson H. E., Fremeau R. T., Jr. Caron M. C., Peek M. M. Priace H. K. and Bradley C. C. (1991) Cloning and expression of a functional the 5HT transporter from rat brain. Nature 354, 6670.
  • Blann A. D., Nadar S. and Lip G. Y. (2003) Pharmacological modulation of platelet function in hypertension. Hypertension 42, 17.
  • Brass L. F. (1999) More pieces of the platelet activation puzzle slide into place. J. Clin. Invest. 104, 16631665.
  • Corash L., Costa J. L., Shafer B., Donlon J. A. and Murphy D. L. (1984) Heterogeneity of human whole blood platelet subpopulations. III. Density-dependent differences in subcellular constituents. Blood 64, 185193.
  • Dabire H., Cherqui C., Fournier B. and Schmitt H. (1987) Comparison of effects of some 5-HT1 agonists on blood pressure and heart rate of normotensive anaesthetized rats. Eur. J. Pharmacol. 140, 259266.
  • Doggrell S. A. (2001) Pharmacotherapy of intermittent claudication. Expert Opin. Pharmacother. 2, 17251736
  • Duan S., Anderson C. M., Stein B. A. and Swanson R. A. (1999) Glutamate induces rapid upregulation of astrocyte glutamate transport and cell-surface expression of GLAST. J. Neurosci. 19, 1019310200.
  • Egan B., Conlon M. E., Campbell R., Schork N., Zwiefler A. and Julius S. (1988) Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension. Am. J. Hypertens. 1, 324S330S.
  • Freyburger W. A., Graham B. E., Rapport M. M., Seay P. H., Govier W. M., Swoap O. F. and Vander  Brook M. J. (1952) The pharmacology of 5-hydroxytryptamine (serotonin). J. Pharmacol. Exp. Ther. 105, 8086.
  • Golino P., Piscione F., Willerson J. T., et al. (1991) Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. New Engl. J. Med. 324, 641648.
  • Gujrati V. R., Goyal A., Gaur S. P., Singh N., Shanker K. and Chandravati. (1994) Relevance of platelet serotonergic mechanisms in pregnancy induced hypertension. Life Sci. 55, 327335.
  • Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D. and Lesch K. P. (1996) Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66, 26212624.
  • Hoffman B. J., Mezey E. and Browstein M. J. (1991) Cloning of the 5HT transporter affected by antidepressants. Science 254, 579580.
  • Jafri S. M., Chandra N., Dhawan S., Soni D., Chandra M. and Shanker K. (1992) Factors influencing platelet serotonin uptake in essential hypertension. Int. J. Cardiol. 34, 327333.
  • Johnson G. J., Leis L. A., Dunlop P. C. and Weir E. K. (2003) The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J. Thromb. Haemost. 1, 26632668.
  • Kahlig K. M. and Galli A. (2003) Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur. J. Pharmacol. 479, 153158.
  • Kilic F., Murphy D. and Rudnick G. (2003) A Human 5HT Transporter Mutation Causes Constitutive Activation of Transport Activity. (A Human 5HT Transporter Mutation Causes Constitutive Activation of Transport Activity. Mol. Pharmacol. 64, 412.
  • Kilic F. and Rudnick G. (2000) Oligomerization of 5HT transporter and its functional consequences. Proc. Natl. Acad. Sci. USA 97, 31063111.
  • Kocabas A. M., Rudnick G. and Kilic F. (2003) Functional consequences of Homo- But Not Hetero-Oligomerization between transporters for the biogenic amine neurotransmitters. J. Neurochem. 85, 15131520.
  • Koldzic-Zivanovic N., Seitz P. K., Watson C. S., Cunningham K. A. and Thomas M. L. (2004) Intracellular signaling involved in estrogen regulation of serotonin reuptake. Mol. Cell Endocrinol. 226, 3342.
  • Lesch K. P., Bengel D., Heils A., Sabol S. Z., Greenberg B. D., Petri S., Benjamin J., Muller C. R., Hamer D. H. and Murphy D. L. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 29, 15271531.
  • Lesch K. P., Wolozin B. L., Murphy D. L. and Riderer P. (1993) Primary structure of the human platelet 5HT uptake site: identity with the brain 5HT transporter. J. Neurochem. 60, 23192322.
  • Lichtman J. H., Krumholz H. M., Wang Y., Radford M. J. and Brass L. M. (2002) Risk and predictors of stroke after myocardial infarction among the elderly: results from the Cooperative Cardiovascular Project. Circulation 5, 10821087.
  • Ni W. and Watts S. W. (2006) 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin. Exp. Pharmacol. Physiol. 3, 575583.
  • Ozaki N., Rosenthal N. E., Mazzola P., Chiueh C. C., Hardin T., Garcia-Borreguero D., Schwartz P. J., Turner E., Oren D. A. and Murphy D. L. (1994) Platelet [3H]paroxetine binding, 5-HT-stimulated Ca2+ response, and 5-HT content in winter seasonal affective disorder. Biol. Psychiatry 36, 458466.
  • Ozaslan D., Wang S., Ahmed B., Bene A., Kocabas A. M. and Kilic F. (2003) Glycosyl Modification Facilitates Homo- and Hetero-Oligomerization of Serotonin Transporter. A Specific Role for the Sialic Acid Residues. J. Biol. Chem. 278, 4399144000.
  • Pettinger W., Sheppard H., Palkoski Z. and Renyi E. (1973) Angiotensin antagonism and antihypertensive activity of phosphodiesterase inhibiting agents. Life Sci. I. 15, 4962.
  • Pidgeon G. P., Tamosiuniene R., Chen G., Leonard I., Belton O., Bradford A. and Fitzgerald D. J. (2004) Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 26, 27012707.
  • Quick M. W. (2003) Regulating the conducting states of a mammalian serotonin transporter. Neuron 40, 537549.
  • Ramamoorthy S., Cool D. R., Mahesh V. B., Leibach F. H., Melikian H. E., Blakely R. D. and Ganapathy V. (1993a) Regulation of the human serotonin transporter. Cholera toxin-induced stimulation of serotonin uptake in human placental choriocarcinoma cells is accompanied by increased serotonin transporter mRNA levels and serotonin transporter-specific ligand binding. J. Biol. Chem. 268, 2162621631.
  • Ramamoorthy S., Baumen A. L., Moore K. R., Han H., Yang-Fen T., Chang A. S., Ganapathy V. and Blakely R. D. (1993b) Antidepressant- and cocaine-sensitive human the 5HT transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. USA 90, 25422546.
  • Ramamoorthy S. and Blakely R. D. (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285, 763766.
  • Reis F., Tavares P., Rito L. C., Teixeira H. M., Santos  Dias J. D., Ferrer-Antunes C., Mesquita J. F. and Teixeira F. (2000) Platelet activation is increased in cyclosporin A-induced hypertensive rats. J. Cardiovasc. Pharmacol. 36, 5664.
  • Serebruany V. L., Gurbel P. A. and O'Connor C. M. (2001) Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol. Res. 43, 453461.
  • Shulman N. B., Ford C. E., Hall W. D., Blaufox M. D., Simon D., Langford H. G. and Schneider K. A. (1989) Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 180193.
  • Stoddard M. F., Singh P., Dawn B. and Longaker R. A. (2003) Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am. Heart J. 145, 676682.
  • Towbin H., Staehelin T. and Gordon J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76, 43504354.
  • Yildiz O., Cicek S., Ay I., Demirkilic U. and Tuncer M. (1996) Hypertension increases the contractions to sumatriptan in the human internal mammary artery. Ann. Thorac. Surg. 62, 13921396.
  • Yildiz O., Smith J. R. and Purdy R. E. (1998) Serotonin and vasoconstrictor synergism. Life Sci. 62, 17231732.
  • Watts S. (2005) 5-HT in systemic hypertension. Clin. Sci. 108, 399412.
  • Willerson J. T. (1995) Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products. Tex Heart Inst. J. 22, 1319.
  • Woittiez A. J., Wenting G. J., Van Den Meiracker A. H., Ritsema van Eck H. J., Man in't Veld A. J., Zantvoort F. A. and Schalekamp M. A. (1986) Chronic effect of ketanserin in mild to moderate essential hypertension. Hypertension 8, 167173.
  • Wocial B., Wasowska-Ciszek T., Lapinski M., Januszewicz A., Grzesiuk W., Stepniakowski K. and Januszewicz W. (1990) Free serotonin level in the blood of patients with borderline and essential hypertension. Kardiol. Pol. 33, 47.
  • Wuller S., Wiesner B., Loffler A., Furkert J., Krause G., Hermosilla R., Schaefer M., Schulein R., Rosenthal W. and Oksche A. (2004) Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J. Biol. Chem. 279, 4725447263.